IceCure Medical Ltd (ICCM) Earnings Call Transcript
March 17, 2026
Earnings Call Speaker Segments
Thanks, Ella. And hello everyone — I appreciate you joining IceCure Medical's call today, where we'll go over the financial results for the 12 months that closed on December 31, 2025, and share an update on what's been happening operationally. Earlier this morning we put out the earnings press release, so feel free to follow along with that. Our CEO, Eyal Shamir, is here with us on the call. Unfortunately, our VP in sales North America, Shad Good, couldn't make it because of connectivity issues, so I'm going to read the statement he prepared. Shay Levav, who serves as the company's COO, will be around for the Q&A portion. Before we dive in, I want to briefly cover our required language about forward-looking statements. On this call, and in the Q&A that follows, we'll be making forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, along with other federal securities laws. Words such as expects, anticipates, intends, plans, believes, seeks, estimates, and similar terms or variations of them are intended to identify forward-looking statements. For instance, we're using forward-looking statements in this presentation when we talk about the FDA's marketing authorization for ProSense driving meaningful growth for us. Things we're watching include the ProSense post-marketing trial, more ProSense systems being installed as our customer pipeline expands—medical clinics and hospitals among them—the possibility of higher CPT code reimbursement, and growing curiosity about ProSense among breast radiologists and surgeons. Any forward-looking statements made or suggested on this call carry additional risks and uncertainties, and a great many of those sit outside the company's control, such as the ones listed under the Risk Factors section in our annual report on Form 20-F for the year ended December 31, 2025, which is set to be submitted to the SEC on March 17, 2026 and can be found on the SEC's website at www.sec.gov. Except where legally mandated, the company states it has neither plans nor duties to refresh or amend any forward-looking statements, including in response to fresh data, upcoming occurrences, or other developments. Information shared on this call is sensitive to timing and reflects circumstances only up to the moment of today's live transmission on March 17, 2026. At this point I'll pass the discussion to Eyal Shamir, who serves as CEO of IceCure Medical. Eyal, you have the floor.
Michael, thank you. During our update in early January, we noted that Q4 revenue reached an all-time high of roughly $1.3 million, lifting full-year sales revenue to a record $3.4 million for the period ending December 31, 2025. Driving that growth were unprecedented domestic sales, reflecting the positive effect of U.S. FDA clearance in low risk early-stage breast cancer, along with growing ProSense uptake in major markets. Since our time is limited and Shad and I have lots of exciting developments to discuss, we ask that you refer to this morning's press release for the full financial results. During this call, our main focus will be IPO's strong commercial performance worldwide. Several factors are driving that momentum: regulatory clearances, updated guidance from a medical society that now backs cryoablation for early-stage cancer in low-risk patients, a widening body of independent research demonstrating growth along with efficiency and safety benefits, and rising awareness and recognition of this approach's value among physicians and patients both in the United States and internationally. In October 2025, the U.S. FDA cleared ProSense for treating low risk breast cancer in women who are 70 or older, and also for those who cannot undergo surgery. Beyond that, in our view the adoption catalyst for ProSense that stands out most recently is the 2026 statement from the American Society of Breast Surgeons, or ASBrS. Last week we shared that the ASBrS has put forward cryoablation as a choice for certain patients who have biological low-risk early stage breast cancer. It's great to see a top professional society give cryoablation this level of recognition, since that group represents the very end users we're targeting, and we think this could be a major catalyst as more validation comes in, confirming ProSense's place in contemporary breast cancer treatment as an option centered on outcomes, cosmetic results and patient choice. This recommendation helps patients and doctors as they decide whether to pursue cryoablation, and it also backs additional growth in reimbursement. Just to note, ProSense holds a unique position—it's the sole medical device with FDA clearance for treating breast cancer, and it was also the first of its kind. We don't see rival firms bringing cryoablation devices for breast cancer into the U.S. market in the near future. That's because the FDA's market authorization made clear that any competitor seeking 510(k) clearance for a separate cryoablation system aimed at breast cancer would need to provide complete clinical study follow-up data. Based on our recent announcements, you've likely noticed that in the U.S. our customer pipeline keeps expanding. Medical clinics and hospitals are moving toward signed agreements, taking delivery of ProSense, and getting it installed. Beyond names like <<inaudible>>, imaging, and Thomas Hospital that we've already shared, there are also well-known hospitals ramping up their ProSense installations and procedures that we aren't able to identify. A major university hospital in the Southeast is one example. Another ranks among the most respected medical institutions globally, and it currently operates a ProSense system at two of its biggest locations. With this prestigious hospital network, we see room to place more systems. I'd like to add as well that the two most recent customer announcements we made have obviously had a commercial angle. Those aren't tied to any post-marketing study work; our expectation is that momentum will build, pulled along by demand from patients as well as physicians, with every additional installation and that flywheel effect. Take, for instance, the ProSense installation done recently at Thomas Hospital in Alabama — the one we told you about in February — which came about thanks to a really compelling segment on a local news outlet. That broadcast aired on February 25 over WKRG, a CBS affiliate based in Fairhope, Alabama; we'd encourage you to take a look at the community story and the need it illustrated, both of which are in our earnings release that went out earlier today. According to one of the physicians at that hospital, cryoablation using ProSense is a life-giving, life-extending technology that managed to successfully cure a 90-year old breast cancer patient in 30 minutes. To drive the point home, this doctor continues by noting that you can't even get a pizza delivered in that same span of time; our view is that organically driven interest much like this will emerge in local markets where the right patient demand exists. Now, about the medical conferences we're attending: April brings us 231 events across the U.S., including the Society of Breast Imaging Symposium and the American Society of Breast Surgeons' annual meeting. Those give us a chance to connect face-to-face with the exact audience we're going after. Historically, we'd show up and exhibit at a maximum of two big new conferences, using that as a way to teach the medical community. But with the FDA clearance and the ASBrS recommendation in hand, there's a real sense of urgency now, so we think physicians will be ready to act immediately on the interim importance. And remember — this is the first time we've ever been able to promote ProSense for breast cancer. Interest levels among radiologists and surgeons are climbing as anticipated, with roughly half of our customer pipeline coming from each of those two specialties. I'll now hand the call over to Mike and team, who'll give you more detail on U.S. commercial activity. Before that, though, I want to say a bit more about global sales momentum for ProSense. Our belief that FDA clearance would fuel demand in other markets where ProSense already held approval for breast cancer is proving correct. Regulatory validation in the U.S. has boosted confidence and uptake internationally, particularly in Europe, which reflects robust demand and a broader market presence. Where IceCure already had a presence, we saw the business grow into additional clinical uses, particularly breast cancer and other interventional oncology indications. As of yesterday, we submitted an amended Class III application to Health Canada, seeking to expand our current regulatory clearance so that it includes treating early stage low-risk invasive breast cancer in patients age 60 years old in August with the ProSense cryoablation system. Backing that submission is data from our ICE3 study, together with the U.S. FDA marketing clearance of ProSense for low risk breast cancer treatment. For the indication we have put forward in Canada, approximately 7,130 women diagnosed with low risk breast cancer could be eligible for cryoablation. As far as our applications go, we anticipate a ruling from Health Canada at some point in the latter half of 2026, though that depends on the agency's standards regarding new procedures and any follow-up questions that may arise. On a global scale, data grounded in evidence along with peer-reviewed presentations and abstracts are boosting ProSense's agitation, and independent studies that are currently in progress will lift ProSense's worldwide exposure even further. Take, for instance, the SIX study, which Dr. Vanessa Sanvido leads along with renewed breast surgeons in Brazil, and the PRECICE study in Italy, headed by Professor Franco Orsi, an interventional radiologist and key opinion leader — both are anticipated to deliver meaningful clinical evidence. Beyond that, social media plays a big role in promoting these trials as a patient recruitment tool, which boosts visibility and familiarity with ProSense among patients and advocacy groups. In 2025, we set a record for peer-reviewed publications and ProSense presentations, and we've already seen a number of additional ones in early 2026. Over the course of 2025, 63 principal investigators presented data at 10 conferences around the globe, covering the U.S., Europe and Asia. It's heartening to see a growing number of international conferences now featuring new breast cryoablation <<inaudible>> so that physicians can learn about the minimally invasive choices we provide. A very strong showing, backed up by separate research and published work, has greatly widened visibility worldwide and is driving growing interest in bringing IceCure systems into use for breast tumors and breast cancer treatment, along with the additional indications ProSense is cleared for. With that, I'll hand things over to Michael so he can give us more detail on the U.S. American markets. Michael?
Thanks, Eyal. For a while now, we've been aware of how much interest there is in the U.S. regarding ProSense for breast cancer, and that's been fueled by IceCure taking an active part in medical industry conferences at the 19 ICE3 clinical sites. On top of that, the strong interim results and the final ICE3 data have helped that interest keep building, alongside every successful milestone submission for FDA clearance, the result from the FDA's advisory panel, and then, naturally, the FDA clearance itself. As I see it today, 3 forces have come together to speed up adoption in the U.S. First, ProSense has its FDA clearance; second, we've secured reimbursement; and third, the ASBrS has issued new guidelines that recommend cryoablation for low risk breast cancer. We're seeing a clear rise in interest and engagement from patient facilities. Eyal already went over some of the newest customers, which came from our higher activity in the fourth quarter of last year and the first quarter of 2026. We think we'll complete a growing number of system sales and installations in the second quarter, with further growth in the quarters that follow in 2026. We're expanding our U.S. commercial organization to meet demand. Our core sales team is putting in hard work on the ground at sites and in the priority territories we're targeting. By year-end, we plan to triple our commercial team, in line with rising momentum and demand, with the goal of achieving broader penetration across the U.S. Our customers already do ultrasounds and needle biopsies routinely, and that procedure calls for many of the same skills that cryoablation requires. What's more, ProSense is simple to implement and has no need to tap into the hospital's IT systems. From a hospital's point of view, there's no extra infrastructure investment required. We believe the real champions inside the hospital and clinic are the surgeons and radiologists who deliver care. Our wish and aim is to engage the departments that directly provide that care. Depending on how large the customer is, from small privately owned clinics all the way to the biggest and most prestigious hospital networks in the U.S., the sales cycle process, from lead to contract installation, can take on average anywhere from a few months to 9 months. Although interest has been very strong among potential customers who want to use ProSense commercially, we're also seeing plenty of interest from clinics and hospitals that want to join our recently FDA approved, post-marketing study and use ProSense commercially as well. Many of the sites in our customer pipeline have been holding off on acquiring a system until the post-marketing study gets underway. We expect our post-marketing study to considerably accelerate the national rollout and availability of ProSense. The FDA's requirement is to have 30 sites for the PMS. Most of these 30 sites have been identified, and we expect the onboarding process to begin in the next 3 to 6 months, with all 30 to be opened by the end of next year. Every PMS location is going to agree to carry out commercial procedures on individuals who aren't part of the trial. We're set to begin enrolling patients in late summer, and by this same point next year we should hit 20% enrollment. Just a note that reimbursement is available for the post-marketing study procedures. Our facility cost is covered by the CPT 3 code, and that comes to roughly $4,000. That said, after ProSense received FDA clearance, the company submitted an application for transitional pass-through, or TPP, payment, and that could bring in as much as an extra $900 per procedure by early '27. We've also been collaborating with medical societies and associations to file the CPT 1 reimbursement covering physician costs during the second quarter of this year. Early '27 is when we anticipate a response, with a CPT 1 taking effect in early 2028. What we're seeing in the U.S. market gives us a lot of encouragement, and we think Canada could show comparable patterns, where ProSense will gain approval for breast center. Eyal has already told you about the significant momentum in growth markets, which stems partly from the FDA's clearance. We're putting in serious effort to bring ProSense to additional clinics and hospitals, so that more women are able to access noninvasive choices for breast cancer. At this point I'll hand the call to Ella for Q&A. Thank you.
Thanks. Might you provide additional specifics about how you intend to secure reimbursement coverage outside of Medicare? My guess is you likely need to engage Medicare Advantage plans, perhaps the VA, and possibly a few other smaller groups so that coverage extends across the approved population.
Eyal here. I appreciate the question. I'll hand this over to Shay Levav, our COO, who additionally handles regulatory and reimbursement matters. Shay, go ahead.
Thanks, Eyal. Now, when it comes to reimbursement, we're operating right now with the CPT 3 code, and the payment there is quite favorable at $4,000. Following the FDA approval, what we've observed is that reimbursement has become steadier. We've got a payer outreach program up and running, and through it we reach out to private payers. Our attention is on the Medicare advantage program, given the patient population described in the labeling the FDA granted us. Beyond that, we keep pushing to raise payment levels and, naturally, to make the move to CPT 1.
Great. So, another thing I wanted to ask — once you have that CPT 1 code secured, do you expect it to drive more demand, and I mean meaningfully more? Or is the real benefit simply improved reimbursement based on what the market has shown you up to now?
Yes. Kemp, thanks. Everybody knows CPT 1 also forms part of the standard of care here in the U.S., and naturally, our plans involve expansion during '26 and '27, yet we think the upcoming inflection point for us arrives in early '28, once CPT 1 has been obtained. So obviously total reimbursement will get better, but in our view this will be a key moment allowing IceCure to expand far more quickly and to a greater extent.
A few things I'd like to ask. Regarding those 30 hybrid commercial clinical sites, you said over 50% have already been located. Could you be more precise? Are there at least 20 or 25 that you've pinpointed? Then I'd appreciate some detail on the ramp, since I'm aware you've been getting ready for it. What's your sense of how fast you can scale that up? Also, I have a question about Japan, and one about Canada.
Shay, since you're the COO, that falls under your responsibility — you can take the first answer about how many sites will be included in our PMS, and also address the production and manufacturing ramp-up.
Yes, thanks. As for the post-market study, 30 sites are mandated. We're seeing a lot of enthusiasm from those sites, and while it's still early days, we've already pinpointed the sites the study requires. Following FDA approval, the team is now collaborating with the CRO to confirm those sites satisfy every requirement, and that we can transition them to the PMS side while also making them commercial simultaneously.
So every one of those 30 locations has been pinpointed, and for each of these clinical locations, a condition that applies to most — possibly all — of them is that they must also serve as commercial locations, which it sounds like nearly all of them would be eager to do too. They've been pinpointed, and it's simply a question of your team reviewing the criteria needed to formally qualify as a clinical location. There's a certain amount of personnel effort tied to that, and you've got a CRO helping with it. Is that right?
Yes. I'd just like to stress that the locations have been pinpointed by us; we're seeing strong interest from locations throughout the U.S. The post-market study agreements haven't all been signed by us. That remains something currently underway. Still, given the interest and the effort being put in, we're quite confident that we'll advance quickly with those locations.
Alright; you also mentioned that a submission has been made in Canada seeking regulatory clearance, with the hope of securing it prior to the close of this year. Could you discuss what that market offers? Since I believe the age threshold there could be younger than what we have here — here it's 70 and up, whereas in Canada is it 60 and up? And what kind of opportunity does that present? Then finally, any news regarding Japan. From what I understand, you're collaborating with Terumo, which I think ranks as that country's biggest medical device manufacturer, on a filing for Japan. So if you could touch on both of those, that would be wonderful.
Eyal, would you like me to take those?
Yes, please.
All right. Regarding the indication we filed in Canada, the submission was for the ICE3 indication, covering patients aged 60 and above. Each year in Canada, that accounts for slightly over 10,000 new cases. In Japan too, as you noted, we're collaborating with Terumo, and following the FDA, Terumo has already kicked off its work with the PMDA. Their initial general consultation with the PMDA has taken place, and the results were favorable, with a few comments they need to address. Another discussion with the PMDA is being planned, and right after that, they intend to make the formal submission in Japan.
We appreciate everyone being with us on today’s call. IceCure has reached an unmistakable inflection point, thanks to the FDA clearance and the Medical Society recommendation in the U.S.; our commercial pipeline keeps expanding, and we anticipate turning this prospective customer into ProSense installations, allowing women to receive the minimally invasive choice they are entitled to. Everyone, have a good day. Operator?
That wraps up the IceCure conference call covering results for the fourth quarter and the full year of 2025. We appreciate everyone taking part. You're welcome to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete IceCure Medical Ltd transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to IceCure Medical Ltd earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.